split-banner-image

MA.27

Closed

NCIC CTG MA.27/IBCSG 30-04: Exemestane vs Anastrozole

BCT Study Chair:

John Forbes

A randomised phase III trial of exemestane vs anastrozole in postmenopausal women with hormone receptor-positive primary breast cancer.

international

7462

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

114

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

15

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

MA.27 PUBLICATIONS

2024

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155,746 women in 151 trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Lancet 2024; 404(10461):1407-1418, epub 12 October 2024, Journal

Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials.

Pan H, Gray R, on behalf of the EBCTCG. Journal of Clinical Oncology. 2024; 32:5s(SABCS 2024), [Abstract Number SESS-1911; GS2-09], Abstract

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.

Early Breast Cancer Trialists’ Collaborative Group. The Lancet. 2024; 4041407-18, epub 12 October 2024, E-pub

Adjunctive statistical standardization of adjuvant estrogen receptor and progesterone receptor in Canadian Cancer Trials Group MA.27 postmenopausal breast cancer trial of exemestane versus anastrozole.

Chapman J-AW, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA, Virk S, Goss PE, Ingle JN, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Tozer R, D’Souza DP, Chalcal H, Spadafora S, Stearns V, Perez EA, Gelmon KA, Whelan TJ, Elliot C, Shepherd LI, Chen BE, Taylor KJ. Journal of Clinical Oncology. 2024; 42(24):2887-2898, Journal

2017

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.

Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard KI, Ingle JN, Budd GT, Ellis MJ, Sledge GW, Rabaglio M, Han L, Elliott CR, Shepherd LE, Goss PE, Ali SM. Cancer. 2017; 123(13):2444-2451. epub 2 May 2017; doi: 10.1002/cncr.3068, Journal

2015

Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial.

Stearns V, Chapman J-AW, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PER, Shepherd LE, Goss PE. Journal of Clinical Oncology. 2015; 33(3):265-271, Journal

LOAD MORE

Institutions